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Gitelman’s syndrome revisited: An evaluation of symptoms and Gitelman’s syndrome (GS) is an autosomal recessive
health-related quality of life. renal disorder first described by Gitelman, Graham, and
Background. Gitelman’s syndrome (GS), also called Gitel- Welt [1]. This syndrome is characterized by hypoka-
man’s variant of Bartter’s syndrome, is an autosomal recessive lemia, hypomagnesemia, metabolic alkalosis, and hypo-
renal disorder characterized by hypokalemia, hypomagnese-
calciuria and is caused by inactivating mutations in themia, metabolic alkalosis, and hypocalciuria. GS is caused by
thiazide-sensitive sodium chloride cotransporter geneinactivating mutations in the thiazide-sensitive sodium chloride
(NCCT) [2–6]. In contrast, patients with “true” Bartter’scotransporter gene (NCCT). It is also known as the “milder”
syndrome have hypokalemia, metabolic alkalosis, normo-form of Bartter’s syndrome, as patients with GS are usually
diagnosed in adulthood during routine investigation. Symp- hypercalciuria, and normal serum magnesium levels,
toms reported in the literature range from asymptomatic, to caused by defects in the Na-K-2CL cotransporter gene
mild symptoms of cramps and fatigue, to severe manifestations (NKCC2), renal potassium channel gene (ROMK), or
such as tetany, paralysis, and rhabdomyolysis. This is the first the renal chloride channel gene (CLCNKB) [7–10]. Fol-
systematic evaluation of a large group of patients with geneti-
lowing Gitelman’s initial report, many other cases of GScally defined GS.
have been reported in the literature, although some areMethods. We evaluated the symptoms and quality of life
labeled as Bartter’s syndrome [11–20]. In contrast to(QOL) in 50 adult GS patients with confirmed mutations in
NCCT, using a standardized questionnaire. This cohort was patients with “true” Bartter’s syndrome who are symp-
compared with 25 age- and sex-matched controls. tomatic in childhood, patients with GS are usually diag-
Results. GS patients were significantly more symptomatic nosed in adulthood during routine investigation [21].
than controls. The most common symptoms were salt craving, Some reports indicate that patients are generally asymp-
with musculoskeletal symptoms such as cramps, muscle weak- tomatic at presentation [19, 20, 22]. Other reports rangeness, and aches and constitutional symptoms such as fatigue,
from symptoms of mild weakness, cramps, and fatiguegeneralized weakness and dizziness, and nocturia and polydip-
to severe presentations such as tetany, paralysis, andsia. Forty-five percent of GS patients consider their symptoms
rhabdomyolysis [11, 14, 23–28]. Thus far, there has beena moderate to big problem. Measures of health-related QOL
were significantly lower in GS patients compared with controls, no comprehensive description of the symptomatology of
particularly in terms of role limitations caused by physical this disease in a large group of patients proven to have
health, emotion, level of energy, and general health perception. mutations in NCCT. This study was performed to de-
Conclusions. This descriptive study indicates that GS is not scribe the prevalence and spectrum of symptoms in pa-
an asymptomatic disease and adversely affects QOL in these tients with genetically confirmed GS and to assess thepatients. Further studies are needed to assess the impact of
effect of their disease on quality of life (QOL).therapy on symptoms and QOL.
METHODS
Key words: Bartter’s syndrome, hypokalemia, potassium, magnesium, Patientssodium-chloride cotransporter, genetically confirmed Gitelman’s syn-
drome. The study population consisted of 50 adult GS patients
from 36 kindreds in the United States, Canada, and En-Received for publication December 22, 1999
gland. They represent a cohort of patients diagnosedand in revised form August 31, 2000
Accepted for publication September 5, 2000 with GS referred to our institution between July 1, 1994,
and November 30, 1997, for testing for mutations inÓ 2001 by the International Society of Nephrology
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Table 1. Demographic characteristics of study population the exception of carpopedal spasm/tetany and paralysis.
These were considered as specific medical conditionsGitelman’s syndrome Controls
(N 5 50) (N 5 25) P that can be correctly identified by only trained medical
Current age years 40.5612.5 (17–74)a 40.5612.1 (19–68)a NS personnel; therefore, the prevalence of these two symp-
Age at diagnosis of toms was based on physician reporting.GS years 28.662.1 NA NA
Quality of life according to the patient’s own percep-Sex 15 M/35 F 8 M/17 F NS
Race 49 W/1 A 25 W NS tion was assessed using the RAND health survey, which
Employment status 67% full time 56% full time NS comprised 36 items within the questionnaire [31–33].15% part time 36% part time
Marital status 70% married 68% married NS QOL scores range from 0 to 100, with higher scores
30% unmarriedb 32% unmarriedb reflecting a better QOL [31–34].
Abbreviations are: GS, Gitelman’s syndrome; M, male; F, female; W, white;
A, Asian; NA, not applicable; NS, not significant. Genetic testsa Reported as mean 6 SD (range)
b Includes widowed, divorced, never married Genomic DNA was prepared from venous blood sam-
ples by standard procedures [35]. The mutations in
NCCT were identified by single-stranded conformation
polymorphism, using polymerase chain reaction (PCR)NCCT, in whom such mutations were identified (dis-
primers designed from intronic sequences surroundingcussed later in this article). Of the 50 GS patients, 44
all 26 NCCT exons, as previously described [2]. Thewere on some form of therapy for their disease at the
deletion of exons 1 through 7 in two subjects in this reporttime of the study. Such therapy included potassium (N 5
was determined by the absence of PCR amplification of44) and magnesium (N 5 35) supplements, potassium-
exons 1 through 7 using intronic NCCT primers and wassparing diuretics (N 5 24), nonsteroidal anti-inflamma-
confirmed by Southern hybridization of genomic DNAtory agents (N 5 2), and angiotensin-converting enzyme
inhibitors (N 5 3), and several patients were on a combi- digested with Bgl II and hybridized to a 32P-labeled
nation of agents. The control group consisted of 25 nor- cDNA probe corresponding to exons 1 through 7 of the
mal volunteers from the Yale New Haven Medical Cen- NCCT gene. The mutations in this study population are
ter area, matched for age and sex. The demographic listed in Table 2. These included missense variants (N 5
characteristics of both groups are shown in Table 1. 57 alleles), splice site variants (N 5 22 alleles), premature
termination codons (N 5 7 alleles), frame shift variants
Symptom questionnaire (N 5 4 alleles), and deletion of exons 1 through 7 (N 5
A standardized 117-item symptom questionnaire was 3 alleles). We identified only a single mutant allele in 7
administered by telephone interview in similar fashion out of 50 patients (patients 15, 31, 33, 35, 36, 47, and
to all participants by one of the investigators (A.J.S.), 50). The variants in these seven patients are present in
and the results of this survey form the substance of this at least one other GS patient tested in our laboratory
report. Referring physicians were asked to provide infor- and have not been detected in any of 160 chromosomes
mation regarding patient symptoms at the time blood from unrelated Caucasian control subjects. Twelve of
samples were submitted to our laboratory for genetic the patients in this study are homozygous for a specific
testing. Based on a review of over 200 clinical informa- variant (Table 2), while the rest are compound heterozy-
tion sheets, the questionnaire was constructed to include gotes. Six of the GS kindreds represented in this group
all symptoms described therein. The questionnaire in-
have been previously reported [2].
cluded an assessment of both frequency and severity
of symptoms. Patients were asked in the questionnaire Laboratory tests
about their urinary habits. In order to compare the preva-
Gitelman’s syndrome patients had laboratory valueslence of symptoms between GS patients and controls,
for plasma potassium, magnesium, bicarbonate, and urinethe following definitions were made a priori. Polyuria
calcium/creatinine ratios provided to the investigators atwas defined as voiding urine at least five times during
the time their blood samples were submitted for geneticthe daytime. Nocturia was defined as voiding at least
testing. All patients exhibited hypokalemia (mean, 2.6 6once during sleeping hours; enuresis was defined as bed-
0.5 mmol/L), hypomagnesemia (mean, 1.2 6 0.2 mg/dL),wetting past the age of 10 years. Polydipsia was defined
and metabolic alkalosis (mean, 31.6 6 2.7 mmol/L). Theas a self-reported fluid intake of “considerably more fluid
mean urine calcium/creatinine ratio was 0.10 6 0.09than other people around him/her.” A detailed dietary
mmol/mmol. All control subjects had routine laboratoryrecall of the subject’s food and fluid intake on the day
tests, including serum potassium levels, done in theprior to the interview was used to quantitatively estimate
course of their routine general medical care, and nonedaily fluid intake [29, 30]. All percentages reported in
Table 3 are based on the symptom questionnaire, with have a history of hypokalemia.
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Table 3. Prevalence of symptoms in Gitelman’s syndromeStatistical analysis
Gitelman’sThe data are presented as mean 6 SD, unless other-
syndrome Controlswise stated, or as percentages, where appropriate. QOL
% Pscores and symptoms in the GS and control groups were
Generalcompared using Student t test for continuous variables,
Fatigue 82 68 0.172and chi square for categorical variables, with two-tailed Dizziness 80 40 0.0005
P values. A similar analysis was performed comparing Fainting 34 0 0.0009
Musculoskeletalmale and female GS patients.
Generalized weakness 44.2 0 ,0.00001The relationship between laboratory values (serum Muscle weakness 70 4 ,0.00001
potassium, magnesium, and bicarbonate) and QOL was Cramps 84 40 0.0001
Carpopedal spasm/tetanya 11.7 NA NAexplored utilizing the Pearson correlation coefficient.
Muscle stiffness or pain 52 28 0.048In addition, GS patients were grouped into tertiles of Paralysisa 6 NA NA
serum potassium, magnesium, and bicarbonate levels. Arthralgia 54 36 0.141
RenalThe QOL scores of lowest and highest tertile groups
Nocturia 80 24 ,0.00001for each of these laboratory parameters were compared Polydipsia 64.6 36 0.066
using the Student t test. To determine whether GS pa- Polyuria 50 16 0.004
Thirst 76 12 ,0.00001tients with more severe degrees of hypokalemia/hypo-
Enuresis 11.9 4 0.273magnesemia/metabolic alkalosis are more symptomatic Salt craving 90b 20 ,0.00001
than other GS patients, symptom prevalence between Hypotension 62 12 0.00004
Gastrointestinalcthe lowest and highest tertile groups of laboratory values
Vomiting 8 NA NA
were compared using chi square analysis. Constipation 16 NA NA
Abdominal pain 16 NA NACalculations were performed using SPSS 6.1 for Mac-
Paresthesias 78 20 ,0.00001intosh (SPSS Inc, Chicago, IL, USA). A P value of , 0.05
Palpitations 62 24 0.002
was considered statistically significant.
NA is not applicable.
a As indicated by referring physician (Methods section)
b Noted as an adult 90%; noted as a child 87.8%
c Patients were asked if they experienced these symptoms when they had lowRESULTS
potassium and/or magnesium levels, therefore not applicable to controls
Symptoms
The prevalence of symptoms in this study is shown in
Table 3. GS patients were more symptomatic than the the frequency and severity of the fatigue were worse in
controls for most complaints. Prevalence rates are based the GS patients. In terms of frequency, 22% of patients
on the questionnaire, with the exception of carpopedal suffer from fatigue “all of the time,” while none of the
spasm, tetany, and paralysis, which are specific medical controls did so. In terms of severity, many GS patients
diagnoses and therefore based solely on physician re- also rated their fatigue as a “big problem,” while none
porting. The most common symptoms were salt craving, of the controls did this. Over half of the GS subjects
musculoskeletal symptoms such as cramps, muscle weak- suffered from joint pains, however, this was not signifi-
ness, and pain, generalized weakness, and dizziness. cantly different from controls. Joint pains in GS patients
affected mostly affecting the hands/fingers (25%) or knees
Musculoskeletal
(22%). Although chondrocalcinosis has been reported
The overall prevalence of cramps among our cohort to occur in patients with GS [36–38], none of the current
of GS patients is 84%. Among these patients, approxi- cohort had this condition.
mately half experience these muscle cramps frequently, Sixty-five percent of GS patients interviewed for this
most commonly involving the legs and arms. Thirty-two study had been brought to the emergency room (ER) for
percent of GS patients describe their cramps as being their symptoms. The most common symptoms prompting
“moderate to very severe” in intensity. These cramps ER visits were cramps, generalized weakness, muscle
most commonly occur at night (26% of patients) or with paralysis, and vomiting. Of these patients, up to 82%
moderate physical activity (17%), although there is no had received intravenous potassium and/or magnesium
apparent precipitating factor in 33% of subjects. Simi- at least once for their symptoms. Between 16 and 18%
larly, muscle weakness affects mainly the legs (33%) and of our interviewed subjects had been to the ER five or
arms (16%), but many patients describe a “generalized” more times for intravenous potassium and/or magnesium
weakness. Three patients have presented with muscle therapy. The four most severely affected patients de-
paralysis at the time of diagnosis. Although the overall scribed the following: going to the ER once a week for
prevalence of fatigue was not significantly different be- intravenous magnesium for “many” years (N 5 1), going
to the ER for intravenous potassium and/or magnesiumtween GS patients and control subjects (Table 3), both
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Table 4. Quality of life health surveyevery two to three weeks for three years (N 5 2), and
presenting to the ER three to four times per year with Gitelman’s
syndrome Controls Psevere muscle weakness/“paralysis” (N 5 1). These four
Physical functioning 73.7631.7 94.8610.3 ,0.001patients reported compliance with their medical therapy.
Role limitations due toWhether intercurrent illness played a role could not be
physical health 57.0642.6 94.6611.8 ,0.001
ascertained from the questionnaire. Role limitations due to
emotional problems 66.7646.1 90.7626.4 0.006
Energy/fatigue 42.4622.7 73.5611.8 ,0.001Renal
Emotional well-being 54.1621.8 78.868.8 ,0.001
Gitelman’s syndrome patients voided urine more fre- Social functioning 77.0634.7 93.5616.2 0.006
Pain 67.0622.6 86.0610.6 0.003quently than did control patients both during daytime
General health 57.1623.3 84.6611.4 ,0.001hours (5.4 6 2.5 vs. 2.6 6 1.3 times/day, respectively,
P , 0.001) and sleeping hours (2.6 6 1.1 vs. 1.2 6 0.4
times/night, respectively, P , 0.001). The prevalence
of polyuria and nocturia in GS patients, as defined in
ments by their physicians, with a higher dose taken dur-Methods section, was 50 and 80%, respectively, signifi-
ing their menstrual period. Of the 13 nonmenstruantcantly higher than controls (Table 3). Three fourths of
women, 2 reported that their symptoms were better afterthe GS patients reported feeling thirsty frequently. Sixty-
menopause. Twenty of the women had children, of whomfive percent said they drink more than other people
seven had complicated pregnancies. These complicationsaround them, which is represented in Table 3 as polydip-
included the need for intravenous fluids for dehydration,sia. Their mean estimated daily fluid intake was higher
the need for intravenous potassium and/or magnesiumthan that of controls (2.43 6 1.28 vs. 1.89 6 0.42 L/day,
respectively, P 5 0.01). This intake was also higher than administration, severe cramping, Sheehan’s syndrome
mean fluid intake in a large national health survey (infarction of the pituitary gland after substantial blood
(NHANES III, 1.85 6 1.0 L/day) [29]. Salt craving was loss during childbirth), gestational diabetes, miscarriages
also prominent in GS patients. When asked to describe in the first trimester, premature delivery, polyhydram-
food cravings, 64% of GS patients reported food habits nios, preeclampsia, and abruptio placenta. Other than
such as drinking pickle brine, salting cucumbers, and the first two items, it is unclear whether any of these
craving for oranges and tomatoes, starting in childhood complications were related to GS. Six women were ad-
and persisting into adulthood. Four patients described vised by their physicians to avoid future pregnancies
salting lemons and sucking on them. Two patients de- because of their GS.
scribed licking salt blocks used for livestock when they Gitelman’s syndrome patients in the lowest tertile of
were young children. serum potassium and magnesium were more likely to
be diagnosed with hypotension (82 vs. 36%, lowest andOther
highest tertile, respectively, P 5 0.03). In addition, GS
Paresthesias and palpitations occurred with some fre- patients in the lowest tertile of serum potassium were
quency in these GS patients. Overall, 45% of GS patients more likely to have a moderate to big problem with
consider their constellation of symptoms as a moderate cramps (73 vs. 18%; lowest and highest tertile, respec-
to big problem, with fatigue, cramps, and polyuria con- tively, P 5 0.01).
sidered particularly bothersome by 20 to 36% of the
subjects. Other symptoms volunteered by the patients Quality of life
included heat intolerance, forgetfulness, “decreased abil-
Measures of QOL were significantly lower in GS pa-ity to concentrate,” headache, and dyspnea. Four pa-
tients compared with controls, particularly in terms oftients had seizures at least once in their lifetime, but to
role limitations due to physical health, and level of en-their knowledge, these were not directly attributed to
ergy (Table 4). Their self-assessment of general healththeir GS.
was also quite low. A few patients noted that the costThere was no significant difference in prevalence of
of their medications and the large number of pills theysymptoms between men and women. Because of anec-
had to take contributed in part to their low perceptiondotal experience suggesting that symptomatology in
of their QOL. There was no significant difference inwomen with GS is affected by their hormonal status, we
QOL between men and women with GS.included questions regarding this aspect. At the time of
The relationship between laboratory values in GS pa-interview, 22 of the female GS patients were still having
tients and QOL scores was analyzed using Pearson corre-monthly menstrual periods. Of these, eight patients re-
lation. There was no significant correlation between lab-ported that their symptoms were worse during their men-
oratory values and any of the QOL measures examinedstrual period. A few of the women in this study are
prescribed a “sliding scale” for their electrolyte supple- in this report. There was also no significant difference
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in QOL scores between patients at the lowest and highest suggests that they compensate in part by self-selecting
a diet high in sodium and potassium content. Althoughtertile of laboratory values.
our results do not support a difference in symptoms
between men and women, they do support the observa-
DISCUSSION
tion that premenopausal or postmenopausal status may
Gitelman’s syndrome is often described as the milder have some effect on symptoms in women. The mecha-
adult form of Bartter’s syndrome. Individuals affected nism for the latter is not clear. Animal studies have
with this disease are usually first diagnosed in adulthood, shown a difference in NCCT density and thiazide diuretic
as opposed to “true” Bartter’s syndrome, which usually response between genders [41]. Our study population
presents in childhood [21, 39]. Review articles and edito- has a large proportion of women, which may limit the
rials on this disease have noted that the syndrome is detection of a gender difference. A study in ovariecto-
“characterized by a relatively mild course,” that it is mized rats showed an enhancing effect of estradiol on
“often . . . first discovered in adults during routine investi- NCCT density in the distal tubule [42]. Our observations
gation,” and that “many subjects are asymptomatic” [9, in humans may be relevant for future studies. GS also
21, 23]. Case reports and series vary, however, from appears to be a disease that has an impact on health
having “no symptoms of magnesium or potassium defi- care costs, with a significant percentage of patients mak-
ciency,” “mild nonspecific symptoms,” “mild weakness,” ing ER visits, several on multiple occasions. One of the
“minor neuromuscular symptoms” to “frequent tetanic patients in our cohort was confined briefly in a psychiatric
episodes, muscular weakness, or both” [4, 14, 17, 23, 25]. ward for suspected diuretic abuse [2]. We noted a modest
Similarly, 15% of physicians who have referred their correlation between symptoms and laboratory values, in
patients to us for genetic screening in NCCT have re- that patients with more severe degrees of hypokalemia
ported their patients as ”asymptomatic,“ yet the current and hypomagnesemia had a higher prevalence of hypo-
survey of GS patients presents a different picture. This tension and had a bigger problem with cramps. It is likely
descriptive study is the first to evaluate symptomatology that the patients with more severe salt wasting have
and QOL in patients with genetically proven GS in a lower blood pressures and greater stimulation of the
standardized comprehensive manner from the viewpoint renin-aldosterone axis. We hypothesize that the greater
of the patient. degree of salt wasting results in delivery of a larger
Our findings indicate that the prevalence of patient- amount of sodium to the epithelial sodium channel in
reported symptoms in GS is high and that this is not an the cortical collecting tubule, with greater loss of potas-
“asymptomatic” disease (Table 3). In fact, none of the sium in exchange for sodium under the influence of aldo-
patients interviewed were completely asymptomatic. sterone in this nephron segment. The role of magnesium
This is in stark contrast to physician-reported symptoms, in this setting is not clear.
in which the prevalence of salt craving, cramps, and fa- Interestingly, QOL, never previously evaluated in pa-
tigue were 5, 13, and 17%, respectively, and as many as tients with GS, appears to be adversely affected by this
15% were noted to have “no symptoms” (unpublished disease. GS patients have particularly low scores in terms
data). The frequency of symptoms is variable, and this of role limitations caused by physical health, emotion,
may account in part for the discrepancy between patient- level of energy, and general health perception (Table 4).
and physician-reported symptom prevalence. However, In fact, QOL is similar in range to that described for
a significant percentage of patients rate their symptoms more “significant” diseases such as hypertension, diabe-
as being a moderate to big problem, again emphasizing tes, congestive heart failure, and coronary artery disease
the discrepancy between physician and patient percep- (Table 5) [33, 40, 43–46]. It is also comparable to
tion. The most common symptoms are salt craving, mus- “chronic” lung and gastrointestinal disease in terms of
culoskeletal complaints, fatigue, and dizziness. Nocturia, physical function, pain, and general health perception,
polydipsia, polyuria, paresthesias, and palpitations are and slightly worse with respect to role limitation due
also prominent symptoms. Interestingly, fatigue and diz- to physical health, emotion, and social function [44].
ziness are also commonly reported side effects with hy- Perhaps this decreased QOL is related to the cost of
drochlorothiazide therapy for hypertension [40]. NCCT medications, the large number of pills required to main-
is the site of action of these diuretics, and the laboratory tain their electrolytes within reasonable range, as sug-
features of GS are similar to that of a patient on thiazides. gested by some patients, and the limited understanding
GS patients rated fatigue, cramps, and polyuria as partic- of their disease, among other factors. Looking at QOL in
ularly problematic. However, many patients appear to hypertensive patients with thiazide diuretics, GS patients
adapt well to their symptoms, with the majority able to had lower scores (Table 5). This is not surprising since
work full-time or part-time (Table 1), probably contrib- thiazide therapy appears to improve QOL in hyperten-
uting to the perception that this is an asymptomatic dis- sion [40, 46]. Interestingly, we did not find a correlation
between QOL measures and potassium or magnesiumease. The patients’ description of their food cravings
Cruz et al: Symptoms and QOL in GS716
Table 5. Quality of life in Gitelman’s syndrome and other chronic diseasesa
Gitelman’s Hypertension Diabetes Congestive Coronary artery
syndrome Hypertension with thiazideb mellitus heart failure disease/MI
Physical functioning 73.7 73–86 88.3–93.6 68–89 63.5–64 59.8–81
Role limitations due to
physical health 57.0 62–86 78 57–86 53–59 54.2–72
Role limitations due to
emotional problems 66.7 77 NS 76 NS NS
Energy/fatigue 42.4 58 73.8 56
Emotional well-being 54.1 76.5–78 72–80.4 77–77.5 73 74.8
Social functioning 77.0 87–91.2 76.8 82–87 80.9 80.7
Pain 67.0 71.1–75 69–74 71–73.1 71.7–79
General health 57.1 63–69.1 74.2–76.4 56–62 52–59.2 62.7–64
NS is not stated in the referenced article.
a Based on the mean quality of life scores in references [33, 40, 43–46]. Not all references listed scores for all categories
b Values from studies which used a scoring system modified from RAND [40, 46] were converted to equivalent RAND scores
levels. Perhaps these analyses are limited by the number missed as a “mild” disorder, and add a new dimension
in the care of the patient with GS.of subjects. Approximately 60% of patients noted that
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